📊 CTXR Key Takeaways
Is Citius Pharmaceuticals, Inc. (CTXR) a Good Investment?
Citius Pharmaceuticals exhibits severe operational distress with negative operating income of -$9.0M on just $3.9M in revenue, indicating the company is burning cash at an unsustainable rate. Operating losses have resulted in negative free cash flow of -$13.0M annually, with only $7.7M in cash reserves and a current ratio of 0.99x signaling imminent liquidity concerns. The company demonstrates no meaningful revenue growth (0.0% YoY) while operating at massive losses, suggesting fundamental business model challenges.
Citius Pharmaceuticals shows extremely weak operating fundamentals: revenue is essentially flat at a very small base, while operating and net margins remain deeply negative and free cash flow burn is severe. Although leverage is low and the balance sheet is not debt-heavy, liquidity is tight and the company appears dependent on external capital or major business improvement to sustain operations.
Why Buy Citius Pharmaceuticals, Inc. Stock? CTXR Key Strengths
- High gross margin of 80.0% indicates strong unit economics when sales occur
- Minimal debt load with debt-to-equity ratio of 0.01x provides some financial flexibility
- Substantial asset base of $140.4M relative to liabilities suggests underlying asset value
- High gross margin indicates the existing revenue base is not structurally low-margin
- Very low long-term debt and debt-to-equity reduce balance sheet leverage risk
- Positive equity base provides some balance sheet support despite ongoing losses
CTXR Stock Risks: Citius Pharmaceuticals, Inc. Investment Risks
- Negative operating margin of -228.7% demonstrates severe operational inefficiency and inability to cover operating expenses
- Monthly cash burn of approximately $1.1M with only $7.7M in cash represents less than 7 months of runway at current burn rate
- Current ratio of 0.99x and quick ratio of 0.40x indicate critical liquidity stress and potential inability to meet near-term obligations
- Stagnant revenue growth of 0.0% YoY combined with expanding losses suggests loss of market traction or failed commercialization
- Negative free cash flow of -$13.0M annually indicates the company requires external capital to survive
- No insider purchases in last 90 days may reflect lack of management confidence
- Operating losses remain far larger than revenue, with operating margin of -228.7%
- Weak liquidity profile with current ratio of 0.99x and quick ratio of 0.40x
- Negative operating cash flow and free cash flow suggest continued funding pressure if results do not improve
Key Metrics to Watch
- Monthly cash burn rate and months of cash runway remaining
- Quarterly revenue trajectory and pipeline advancement milestones
- Achievement of operating expense reduction or major revenue inflection points
- Capital raising activities and dilution impacts
- Current and quick ratios for liquidity deterioration
- Quarterly operating cash burn relative to cash balance
- Revenue growth and operating margin improvement
Citius Pharmaceuticals, Inc. (CTXR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CTXR Profit Margin, ROE & Profitability Analysis
CTXR vs Healthcare Sector: How Citius Pharmaceuticals, Inc. Compares
How Citius Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Citius Pharmaceuticals, Inc. Stock Overvalued? CTXR Valuation Analysis 2026
Based on fundamental analysis, Citius Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Citius Pharmaceuticals, Inc. Balance Sheet: CTXR Debt, Cash & Liquidity
CTXR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Citius Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-5.97 indicates the company is currently unprofitable.
CTXR Revenue Growth, EPS Growth & YoY Performance
CTXR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.9M | -$9.4M | $-0.38 |
| Q3 2022 | $90.0K | -$4.1M | $-0.05 |
| Q2 2022 | $90.0K | -$4.1M | N/A |
| Q1 2022 | $90.0K | -$8.1M | N/A |
| Q3 2021 | $90.0K | -$4.1M | N/A |
| Q2 2021 | $90.0K | -$4.1M | N/A |
| Q1 2021 | $90.0K | -$4.3M | N/A |
| Q3 2020 | $90.0K | -$3.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Citius Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
CTXR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Citius Pharmaceuticals, Inc. (CIK: 0001506251)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTXR
What is the AI rating for CTXR?
Citius Pharmaceuticals, Inc. (CTXR) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTXR's key strengths?
Claude: High gross margin of 80.0% indicates strong unit economics when sales occur. Minimal debt load with debt-to-equity ratio of 0.01x provides some financial flexibility. ChatGPT: High gross margin indicates the existing revenue base is not structurally low-margin. Very low long-term debt and debt-to-equity reduce balance sheet leverage risk.
What are the risks of investing in CTXR?
Claude: Negative operating margin of -228.7% demonstrates severe operational inefficiency and inability to cover operating expenses. Monthly cash burn of approximately $1.1M with only $7.7M in cash represents less than 7 months of runway at current burn rate. ChatGPT: Operating losses remain far larger than revenue, with operating margin of -228.7%. Weak liquidity profile with current ratio of 0.99x and quick ratio of 0.40x.
What is CTXR's revenue and growth?
Citius Pharmaceuticals, Inc. reported revenue of $3.9M.
Does CTXR pay dividends?
Citius Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find CTXR SEC filings?
Official SEC filings for Citius Pharmaceuticals, Inc. (CIK: 0001506251) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTXR's EPS?
Citius Pharmaceuticals, Inc. has a diluted EPS of $-0.38.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CTXR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Citius Pharmaceuticals, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CTXR stock overvalued or undervalued?
Valuation metrics for CTXR: ROE of -10.3% (sector avg: 15%), net margin of -208.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CTXR stock in 2026?
Our dual AI analysis gives Citius Pharmaceuticals, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CTXR's free cash flow?
Citius Pharmaceuticals, Inc.'s operating cash flow is $-13.0M, with capital expenditures of $6.9K. FCF margin is -330.0%.
How does CTXR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -208.4% (avg: 12%), ROE -10.3% (avg: 15%), current ratio 0.99 (avg: 2).